Nanotechnology Now

Heifer International

Wikipedia Affiliate Button


Home > Press > OctoPlus announces 2009 first half-year results

OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, announces today its results for the six-month period ended 30 June 2009.

OctoPlus announces 2009 first half-year results

Leiden, Netherlands | Posted on August 7th, 2009

Highlights for the first six months

Financial results

- Increase of 168% in revenues to EUR 10.0 million for the first six-month period in 2009 from EUR 3.7 million in 2008

- Revenue growth well on track with previous guidance for the full year of EUR 19 million

- Successful equity raising of EUR 6.0 million (gross) with an international consortium of investors completed in February 2009

- Net loss for the first six-month period significantly decreased to EUR 1.6 million, as a result of the new service-based strategy, despite restructuring costs and costs related to the new manufacturing facility (H1 2008: net loss of EUR 6.4 million)

Operational results

- Collaboration with Biolex Therapeutics for Locteron® progressing as planned

-Significant clinical progress for Locteron with completion of patient enrollment in Phase IIb study; key results expected in the fourth quarter

- New GMP manufacturing facility opened in June

- One-off costs associated with the new manufacturing facility and with the transition to a fully service-based business have been higher than expected, which has had a significant impact on the Company's operating result

- OctoPlus' new CFO Susan Swarte joined the Company in August


- Ongoing success for OctoPlus' new service-oriented strategy with two additional drug delivery technology evaluation contracts signed in 2009


- OctoPlus reiterates the forecasted 2009 revenues of approximately EUR 19 million

Simon Sturge, CEO of OctoPlus comments: "We are very pleased with the accomplishments made in the first six months of 2009. Revenues increased significantly as a result of our new service-based strategy and we were able to report two new drug delivery technology evaluation contracts, the opening of our new manufacturing facility as well as great progress in the clinical development of Locteron. We have been more aggressive in reducing the cost base of the business than originally planned in order to be able to be more competitive in winning new business, and as a consequence restructuring costs in the first half of the year have been higher than expected. These one-off costs, along with final costs related to the new manufacturing facility, have prevented us from being operationally cash flow positive in the first six months of 2009."

Conference call and webcast presentation

OctoPlus will hold a conference call and webcast presentation today at 10:00 AM CET. This event can also be followed live via OctoPlus' website If you would like to participate in the conference call, please dial in on telephone number +31 (0) 45 631 6901. After the presentation, Simon Sturge, CEO of OctoPlus, Susan Swarte, CFO, and Leo Vissers, Financial Controller, will be available to answer questions. After the event, the webcast will be available for replay on the Company's website.

(Read the detailed report here:

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.


About OctoPlus N.V.
OctoPlus is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Biolex Therapeutics' lead product Locteron, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. Locteron is being manufactured for Biolex Therapeutics by OctoPlus and is currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.

For more information, please click here

Rianne Roukema
Corporate Communications
+31 (71) 524 1071

Investor Relations

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New Hopes for Treatment of Intestine Cancer by Edible Nanodrug March 2nd, 2015

Imec, Holst Centre and Renesas Present World’s Lowest Power 2.4GHz Radio Chip for Bluetooth Low Energy March 1st, 2015

Imec, Murata, and Huawei Introduce Breakthrough Solution for TX-to-RX Isolation in Reconfigurable, Multiband Front-End Modules for Mobile Phones: Electrical-Balance Duplexers Pave the Way to Integrated Solution for TX-to-RX Isolation March 1st, 2015

Imec Demonstrates Compact Wavelength-Division Multiplexing CMOS Silicon Photonics Transceiver March 1st, 2015


New Hopes for Treatment of Intestine Cancer by Edible Nanodrug March 2nd, 2015

Imec Demonstrates Compact Wavelength-Division Multiplexing CMOS Silicon Photonics Transceiver March 1st, 2015

onic Present breakthrough in CMOS-based Transceivers for mm-Wave Radar Systems March 1st, 2015

Graphene Shows Promise In Eradication Of Stem Cancer Cells March 1st, 2015

Financial Reports

Aspen Aerogels, Inc. Schedules Fourth Quarter and Fiscal 2014 Earnings Release and Conference Call for February 26, 2015 February 11th, 2015

Arrowhead to Report Fiscal 2015 First Quarter Financial Results February 2nd, 2015

Graphenea sales more than double in 2014 January 29th, 2015

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 2, 2015 January 7th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE